Related references
Note: Only part of the references are listed.miR-203 inhibits melanoma invasive and proliferative abilities by targeting the polycomb group gene BMI1
Xiao Chang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
Leah Ray Strickland et al.
CANCER LETTERS (2015)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Cell cycle control as a promising target in melanoma
Belinda Lee et al.
CURRENT OPINION IN ONCOLOGY (2015)
Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
Igor Puzanov et al.
EUROPEAN JOURNAL OF CANCER (2015)
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Alan E. Siroy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Beyond BRAF: where next for melanoma therapy?
I. V. Fedorenko et al.
BRITISH JOURNAL OF CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Is it time to test biguanide metformin in the treatment of melanoma?
Michael Cerezo et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
EZH2: an emerging role in melanoma biology and strategies for targeted therapy
Jessamy Tiffen et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Benchun Miao et al.
CANCER DISCOVERY (2015)
Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype
Kim H. T. Paraiso et al.
CANCER DISCOVERY (2015)
Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis
Deepika Neelakantan et al.
CELL ADHESION & MIGRATION (2015)
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
Ester Simeone et al.
MELANOMA MANAGEMENT (2015)
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
Chang Xia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Epigenetic biomarkers in skin cancer
Edward S. Greenberg et al.
CANCER LETTERS (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kristel Kemper et al.
CANCER RESEARCH (2014)
SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma
A. Mehrotra et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2014)
Oncogenes in melanoma: An update
Manfred Kunz
EUROPEAN JOURNAL OF CELL BIOLOGY (2014)
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
Judy W. King et al.
FUTURE ONCOLOGY (2014)
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
Jonathan L. Curry et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2014)
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Siwen Hu-Lieskovan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Klaus G. Griewank et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Emilia Caputo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Future perspectives in melanoma research: meeting report from the Melanoma Bridge, Napoli, December 5th-8th 2013
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Discrepant alterations in main candidate genes among multiple primary melanomas
Maria Colombino et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Alexander M. Menzies et al.
LANCET ONCOLOGY (2014)
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Matteo S. Carlino et al.
MOLECULAR ONCOLOGY (2014)
Genome-wide analysis of noncoding regulatory mutations in cancer
Nils Weinhold et al.
NATURE GENETICS (2014)
POT1 loss-of-function variants predispose to familial melanoma
Carla Daniela Robles-Espinoza et al.
NATURE GENETICS (2014)
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
Jianxin Shi et al.
NATURE GENETICS (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
T. M. Becker et al.
ONCOGENE (2014)
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
A. Vultur et al.
ONCOGENE (2014)
Context-specific regulation of cancer epigenomes by histone and transcription factor methylation
M. Sarris et al.
ONCOGENE (2014)
The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
Jennifer A. Lo et al.
SCIENCE (2014)
Profile of selumetinib and its potential in the treatment of melanoma
Dae Won Kim et al.
ONCOTARGETS AND THERAPY (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Clinical Characteristics and Outcomes With Specific BRAF and NRAS Mutations in Patients With Metastatic Melanoma
Amanda D. Bucheit et al.
CANCER (2013)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
Aurora A kinase (AURKA) in normal and pathological cell division
Anna S. Nikonova et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano et al.
CLINICAL CANCER RESEARCH (2013)
Targeting BRAF in melanoma: Biological and clinical challenges
Mario Mandala et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
New developments in biomarkers for melanoma
Klaus G. Griewank et al.
CURRENT OPINION IN ONCOLOGY (2013)
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
A STATement on Vemurafenib-Resistant Melanoma
Edward J. Hartsough et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
Fang Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Maria Colombino et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The FBXO4 Tumor Suppressor Functions as a Barrier to BrafV600E-Dependent Metastatic Melanoma
Eric K. Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
Matteo S. Carlino et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Which drug, and when, for patients with BRAF-mutant melanoma?
Sekwon Jang et al.
LANCET ONCOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
JARID1B expression in human melanoma and benign melanocytic skin lesions
Lukasz Kuzbicki et al.
MELANOMA RESEARCH (2013)
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
I. V. Fedorenko et al.
ONCOGENE (2013)
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
A. P. Rebocho et al.
ONCOGENE (2013)
Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
Ping Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TERT Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn et al.
SCIENCE (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
MEK Inhibition in the Treatment of Advanced Melanoma
April K. S. Salama et al.
CURRENT ONCOLOGY REPORTS (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype
Mickal Ohanna et al.
ONCOTARGET (2013)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
Heike Niessner et al.
CANCER MEDICINE (2013)
Regulation of MMPs During Melanoma Progression: From Genetic to Epigenetic
Antonicelli Frank et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Melanoma and Epigenetic Treatment: Past and Future
Caterina AM La Porta
Anti-Cancer Agents in Medicinal Chemistry (2012)
Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
Karin van den Hurk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth
Deniz A. Ucar et al.
CELL CYCLE (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
Pattern formation in centrosome assembly
Robert Mahen et al.
CURRENT OPINION IN CELL BIOLOGY (2012)
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
Vipin Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Michele Carbone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway
Carlotta Petti et al.
MELANOMA RESEARCH (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting the epigenome for treatment of cancer
E-J Geutjes et al.
ONCOGENE (2012)
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
W. Deng et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Molly Yancovitz et al.
PLOS ONE (2012)
From genes to drugs: targeted strategies for melanoma
Keith T. Flaherty et al.
NATURE REVIEWS CANCER (2012)
Expression of the c-Met Proteins in Malignant Skin Cancers
Yoon-Jin Lee et al.
ANNALS OF DERMATOLOGY (2011)
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Bingbing Dai et al.
CANCER RESEARCH (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling
Jian Chen et al.
CANCER RESEARCH (2011)
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
In vitro and in vivo anti-melanoma action of metformin
Kristina Janjetovic et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Franziska Niehr et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
Marie C. Zipser et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Met Receptor: A Moving Target
Michael J. Clague
SCIENCE SIGNALING (2011)
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment
Russell R. Braeuer et al.
SEMINARS IN CANCER BIOLOGY (2011)
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
T. Tomic et al.
CELL DEATH & DISEASE (2011)
Molecular Network Associated with MITF in Skin Melanoma Development and Progression
Ichiro Yajima et al.
JOURNAL OF SKIN CANCER (2011)
AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival
Jennifer Woodard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Michael Pollak
CANCER PREVENTION RESEARCH (2010)
Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells
Issam Ben Sahra et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Overview of macroautophagy regulation in mammalian cells
Maryam Mehrpour et al.
CELL RESEARCH (2010)
Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
Andrew G. Sikora et al.
CLINICAL CANCER RESEARCH (2010)
Mutation-driven drug development in melanoma
Keith T. Flaherty et al.
CURRENT OPINION IN ONCOLOGY (2010)
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth
Zhijun Luo et al.
FUTURE ONCOLOGY (2010)
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
Keiran S. M. Smalley
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
Kian-Huat Lim et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Cancer stem cells versus phenotype-switching in melanoma
Keith S. Hoek et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
Ryan B. Corcoran et al.
SCIENCE SIGNALING (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
Control of autophagy by oncogenes and tumor suppressor genes
M. C. Maiuri et al.
CELL DEATH AND DIFFERENTIATION (2009)
Genetic risk factors for melanoma
Kathrine Damm Meyle et al.
HUMAN GENETICS (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi
Jingrong Lin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Main roads to melanoma
Giuseppe Palmieri et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
A multi-marker assay to distinguish malignant melanomas from benign nevi
Mohammed Kashani-Sabet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
How Shelterin Protects Mammalian Telomeres
Wilhelm Palm et al.
ANNUAL REVIEW OF GENETICS (2008)
The Aurora kinase family in cell division and cancer
Gerben Vader et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2008)
In vivo switching of human melanoma cells between proliferative and invasive states
Keith S. Hoek et al.
CANCER RESEARCH (2008)
Autophagy in the pathogenesis of disease
Beth Levine et al.
CELL (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Satoru Yokoyama et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
The role of p53 in pigmentation, tanning and melanoma
Neil F. Box et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Claudia Wellbrock et al.
PLOS ONE (2008)
Autophagosome formation: Core machinery and adaptations
Zhiping Xie et al.
NATURE CELL BIOLOGY (2007)
The phosphoinositide 3-kinase pathway in human cancer: Genetic alterations and therapeutic implications
Alexandre Arcaro et al.
CURRENT GENOMICS (2007)
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
Monica Buzzai et al.
CANCER RESEARCH (2007)
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
Weifen F. Zeng et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Issues affecting molecular staging in the management of patients with melanoma
G. Palmieri et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2007)
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
M. Sensi et al.
ONCOGENE (2006)
BRAF somatic mutations in malignant melanoma and melanocytic naevi
NE Thomas
MELANOMA RESEARCH (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
Vikas K. Goel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
MITF: master regulator of melanocyte development and melanoma oncogene
Carmit Levy et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all
Jesus Gil et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Histone deacetylase inhibitors and malignant melanoma
GM Boyle et al.
PIGMENT CELL RESEARCH (2005)
Oncogenic Ras in tumour progression and metastasis
K Giehl
BIOLOGICAL CHEMISTRY (2005)
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma
EE Patton et al.
CURRENT BIOLOGY (2005)
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
RJ Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF
JY Du et al.
CANCER CELL (2004)
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
H Katayama et al.
NATURE GENETICS (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Melanocytes and the Microphthalmia transcription factor network
E Steingrimsson et al.
ANNUAL REVIEW OF GENETICS (2004)
POT1 as a terminal transducer of TRF1 telomere length control
D Loayza et al.
NATURE (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
MR Owen et al.
BIOCHEMICAL JOURNAL (2000)
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
MY El-Mir et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
